Alzheimer's Disease Clinical Trial
— MeMO-RV2Official title:
Usability of Virtual Reality in Subjects With Mild Cognitive Impairment or Alzheimer's Disease. MeMO-RV2
Cognitive and memory problems characterize Alzheimer's disease (AD). Along with these
disorders, psychological and behavioral symptoms (also known as neuropsychiatric symptoms) ,
as well as pathophysiological processes are frequently found and involved significantly in
maintaining autonomy, prognosis and treatment of the disease. Apathy or disorder motivation
is the most common disorder behavior and early stages of cognitive impairment. Apathy is
particularly associated with cognitive difficulties such as attention deficit disorder -
concentration.
In terms of prevention as term care , there is now a broad consensus that interventions on
cognition and behavior must not be limited to pharmacological treatment but should also
promote non-drug approaches.
Interest in video games (serious games and serious games) as intervention support
rehabilitation is growing. Similarly, the virtual reality (VR) and the new information
technologies and communications offer significant opportunities in terms of rehabilitation
and therapeutic assistance.
This protocol is part of a European project to propose techniques for improving the
treatment of people at risk of social exclusion ( VERVE project ) aims .
A first experiment conducted in 2013 showed the acceptability of Virtual Reality (VR) in
healthy elderly subjects. In a second step , it is important to validate the feasibility of
using the RV or in frail subjects with mild cognitive impairment or Alzheimer's disease in
mild to moderate in a clinical environment.
This is a biomedical , randomized given to a group of patients with mild cognitive
impairment or Alzheimer's disease & diseases associated with mild to moderate.
Status | Completed |
Enrollment | 60 |
Est. completion date | February 2015 |
Est. primary completion date | February 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 60 Years and older |
Eligibility |
Inclusion Criteria: - Male or female age = 60 years. - Introducing either: - MCI diagnosis (ICD-10) - diagnosis of Alzheimer's disease or mixed mild to moderate (ICD 10). - Subject undisturbed locomotion requiring the use of a walking aid. - Score at the Mini Mental Test (MMSE) between 16 and 28. Exclusion Criteria: - Presence of psychiatric disorders - Presence of eye diseases causing blurred vision can not be corrected with lenses or glasses. - Presence of auditory pathologies causing a significant decrease in hearing unaided. - High sensitivity to motion sickness. - migraine disease. - Subject epileptic. - Subject vulnerable |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label
Country | Name | City | State |
---|---|---|---|
France | Institut Claude Pompidou | Nice |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nice |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluate the acceptability of the RV | Analog scale assessment of satisfaction from 0 to 100% is given at the end of experience about that evaluates: The general acceptability of the RV His sense of security The environment of RV The degree of motivation |
At the end of experience (45 min) | No |
Secondary | Evaluate the motivation of subjects (interest, cognition) is greater in the virtual environment during the VR experience compared to a conventional cognitive stimulation activity (CSC). | Percentage of membership: relationship between time spent playing in the subject and the total time required by the experiment (Comparison of the two conditions (RV vs SCC)); Degree of performance: number of "cognitive targets" found by the subject during the experiment. (Comparison of the two conditions (RV vs SCC)); Degree of attention: the number of errors in target detection; Evaluation of the degree of presence of participants (condition RV) using the ITC-SOPI. |
At the end of experience (45 min) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Withdrawn |
NCT03316898 -
A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
|
Phase 1 | |
Withdrawn |
NCT02860065 -
CPC-201 Alzheimer's Disease Type Dementia: PET Study
|
Phase 2 | |
Completed |
NCT01315639 -
New Biomarker for Alzheimer's Disease Diagnostic
|
N/A | |
Not yet recruiting |
NCT03740178 -
Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)
|
Phase 1 | |
Recruiting |
NCT05607615 -
A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease
|
Phase 2 | |
Terminated |
NCT03307993 -
Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease
|
Phase 1 | |
Recruiting |
NCT02912936 -
A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease
|
N/A | |
Active, not recruiting |
NCT02899091 -
Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02907567 -
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT02868905 -
Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women
|
N/A | |
Completed |
NCT02580305 -
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
|
Phase 2 | |
Completed |
NCT02516046 -
18F-AV-1451 Autopsy Study
|
Phase 3 | |
Terminated |
NCT02521558 -
Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease
|
N/A | |
Recruiting |
NCT02247180 -
Cognitive Rehabilitation in Alzheimer`s Disease
|
N/A | |
Terminated |
NCT02220738 -
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
|
Phase 1 | |
Completed |
NCT02260167 -
Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol
|
N/A | |
Completed |
NCT02256306 -
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study
|
N/A | |
Completed |
NCT02317523 -
Alzheimer's Caregiver Coping: Mental and Physical Health
|
N/A | |
Withdrawn |
NCT01636596 -
Efficacy of Pulsatile IV Insulin on Cognition and Amyloid Burden in Patients With Alzheimer's Disease
|
N/A |